FigsharePub Date : 2024-10-10DOI: 10.1021/acs.jmedchem.4c01596.s003
Licheng Zhou (10817937), Kaijie Zhou (19831976), Yu Chang (392011), Jianzhang Yang (1614127), Bohai Fan (19831979), Yuhan Su (8868206), Zilu Li (1477513), Rahul Mannan (659367), Somnath Mahapatra (18204790), Ming Ding (178860), Fengtao Zhou (2048431), Weixue Huang (9107440), Xiaomei Ren (345123), Jian Xu (31545), George Xiaoju Wang (13213614), Jinwei Zhang (462455), Zhen Wang (72451), Arul M. Chinnaiyan (59535), Ke Ding (309244)
{"title":"Discovery of ZLC491nas a Potent, Selective, and OrallynBioavailable CDK12/13 PROTAC Degrader","authors":"Licheng Zhou (10817937), Kaijie Zhou (19831976), Yu Chang (392011), Jianzhang Yang (1614127), Bohai Fan (19831979), Yuhan Su (8868206), Zilu Li (1477513), Rahul Mannan (659367), Somnath Mahapatra (18204790), Ming Ding (178860), Fengtao Zhou (2048431), Weixue Huang (9107440), Xiaomei Ren (345123), Jian Xu (31545), George Xiaoju Wang (13213614), Jinwei Zhang (462455), Zhen Wang (72451), Arul M. Chinnaiyan (59535), Ke Ding (309244)","doi":"10.1021/acs.jmedchem.4c01596.s003","DOIUrl":"https://doi.org/10.1021/acs.jmedchem.4c01596.s003","url":null,"abstract":"Selective degradationnof cyclin-dependent kinases 12 and 13 (CDK12/13)nemerges as a new potential therapeutic approach for triple-negativenbreast cancer (TNBC) and other human cancers. While several proteolysis-targetingnchimera (PROTAC) degraders of CDK12/13 were reported, none are orallynbioavailable. Here, we report the discovery of <b>ZLC491</b> as a potent, selective, and orally bioavailable CDK12/13 PROTACndegrader. The compound effectively degraded CDK12 and CDK13 with DC<sub>50</sub> values of 32 and 28 nM, respectively, in TNBC MDA-MB-231ncells. Global proteomic assessment and mechanistic studies revealednthat <b>ZLC491</b> selectively induced CDK12/13 degradationnin a cereblon- and proteasome-dependent manner. Furthermore, the moleculenefficiently suppressed transcription and expression of long genes,npredominantly a subset of genes associated with DNA damage response,nand significantly inhibited proliferation of multiple TNBC cell lines.nImportantly, <b>ZLC491</b> achieved an oral bioavailabilitynof 46.8% in rats and demonstrated potent <i>in vivo</i> degradativeneffects on CDK12/13 in an MDA-MB-231 xenografted mouse model.","PeriodicalId":522957,"journal":{"name":"Figshare","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147906985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}